Compare PCRX & BFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | BFS |
|---|---|---|
| Founded | 2006 | 1993 |
| Country | United States | United States |
| Employees | N/A | 98 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 809.1M |
| IPO Year | 2010 | N/A |
| Metric | PCRX | BFS |
|---|---|---|
| Price | $22.77 | $33.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $30.25 | ★ $44.00 |
| AVG Volume (30 Days) | ★ 515.7K | 40.3K |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 6.92% |
| EPS Growth | ★ 107.44 | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $541,533,000.00 | N/A |
| Revenue This Year | $6.78 | $0.30 |
| Revenue Next Year | $8.54 | $5.67 |
| P/E Ratio | $336.79 | ★ $30.48 |
| Revenue Growth | ★ 26.04 | N/A |
| 52 Week Low | $18.80 | $29.16 |
| 52 Week High | $27.64 | $35.45 |
| Indicator | PCRX | BFS |
|---|---|---|
| Relative Strength Index (RSI) | 41.55 | 39.62 |
| Support Level | $22.13 | $33.14 |
| Resistance Level | $24.20 | $34.99 |
| Average True Range (ATR) | 1.26 | 0.79 |
| MACD | -0.25 | -0.15 |
| Stochastic Oscillator | 8.81 | 18.64 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Saul Centers Inc is a self-managed real estate investment trust which invests in, operates and develops retail and commercial properties. The company's portfolio includes community and neighbourhood shopping centres, office properties, and mixed-use properties. Properties are located in the Washington, D.C. and Batlimore metropolitan areas. Saul Centers operates through two business segments: Shopping Centers segment, which contribute the maximum portion of total revenue; and mixed-use properties.Mixed-Use Properties segment include office, retail and multi-family residential use.